Login to Your Account



Regulatory NEWS

FDA reviewers told agency advisors in briefing docs released Friday that Jardiance (empagliflozin) postmarket data show "substantial evidence" that, for certain adults with type 2 diabetes, the drug reduces the risk of cardiovascular death.

The annual report on the state of Medicare and Social Security is out, and the news for Medicare is not particularly bad for the short term, despite that the projected Part A trust fund depletion date has moved forward two years from last year's projection.

HONG KONG – With a green light from the CFDA, Taiwan antibiotics maker Taigen Biotechnology Co. Ltd. now has the first made-in-Taiwan novel drug marketed in mainland China.

More Regulatory Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: